References
- Global Strategy for the Diagnosis, Management and Prevention of COPDGlobal Initiative for Chronic Obstructive Lung Disease (GOLD)2015 Available from: http://www.goldcopd.org/Accessed April 22, 2015
- SharafkhanehAMajidHGrossNJSafety and tolerability of inhalational anticholinergics in COPDDrug Healthc Patient Saf20135495523526112
- SinghSLokeYKEnrightPLFurbergCDMortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsBMJ20112011342d321521672999
- WiseRAAnzuetoACottonDIOSPIR InvestigatorsTiotropium respimat inhaler and the risk of death in COPDN Engl J Med2013369161491150123992515
- JenkinsCRMore than just reassurance on tiotropium safetyN Engl J Med2013369161555155624131181
- JenkinsCRTiotropium and the risk of death in COPDN Engl J Med2014370548248324482820
- LokeYKSinghSFurbergCDTiotropium and the risk of death in COPDN Engl J Med201430548048124476442
- VerhammeKMvan BlijderveenNSturkenboomMCTiotropium and the risk of death in COPDN Engl J Med2014370548148224476443
- WiseRATiotropium and the risk of death in COPDN Engl J Med2014370548224476441
- FogartyCHattersleyHDiSLDrollmannABronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patientsRespir Med2011105333734221144724
- D’UrzoADKerwinEOverendTD’AndreaPChenHGoyalPOnce daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studiesCurr Med Res Opin201430349350824156566
- SykesDADowlingMRLeighton-DaviesJThe Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropiumJ Pharmacol Exp Ther2012343252052822854200
- D’UrzoADFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res201120111215622151296
- KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
- BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
- ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med2014201414424438744
- ChenWTieyingSYijiangHEfficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease (COPD): the GLOW7 studyB104. It’s No Longer a Secret Service: Updates in COPD PharmacotherapyAmerican Thoracic SocietySan Diego, USA2014A3756A3756
- WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
- SzarfmanAMachadoSGO’NeillRTUse of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports databaseDrug Saf200225638139212071774
- SinghSLokeYKFurbergCDInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA2008300121439145018812535